Use of Sorafenib As an Effective Treatment in an AML Patient Carrying a New Point Mutation Affecting the Juxtamembrane Domain of FLT3
Overview
Affiliations
Jensen C, Montgomery N, Galeotti J, Foster M, Zeidner J J Cell Mol Med. 2022; 26(24):6079-6082.
PMID: 36444394 PMC: 9753433. DOI: 10.1111/jcmm.17608.
Stasik S, Kramer M, Zukunft S, Rollig C, Baldus C, Platzbecker U Front Oncol. 2022; 12:862991.
PMID: 35387132 PMC: 8977490. DOI: 10.3389/fonc.2022.862991.
The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.
Minson K, DeRyckere D, Graham D J Cell Signal (Los Angel). 2018; 2(4).
PMID: 29806049 PMC: 5964994. DOI: 10.4172/2576-1471.1000166.